皮肤性病诊疗学杂志2025，Vol.32Issue(12)：846-851,6.DOI:10.3969/j.issn.1674-8468.2025.12.002
阿普米司特治疗斑块状银屑病的疗效及安全性
Efficacy and safety of apremilast for patients with plaque psoriasis
摘要
Abstract
Objective To assess the efficacy and safety of apremilast in the treatment of plaque psoriasis.Methods Fifty patients with plaque psoriasis were enrolled and categorized into mild,moderate,and severe groups based on disease severity.They received 12 weeks of treatment with apremilast.The psoriasis area and severity index(PASI)scores,as well as PASI50,PA-SI75,and PASI90,were recorded at weeks 0,4,8,and 12.Additionally,the incidence and se-verity of adverse events were recorded.Results Fifty patients included 12 mild cases,33 moder-ate cases,and 5 severe cases.At weeks 4,8,and 12,the PASI scores for mild(0.60±0.40,0.34±0.29,0.27±0.26),moderate(2.43±1.17,1.55±0.94,1.06±0.83),and severe(7.04±0.94,5.26±1.48,4.18±1.55)groups significantly decreased from baseline.The PA-SI50,PASI75,and PASI90 were highest in the mild group(PASI50:75%,100%,100%;PA-SI75:42%,75%,75%;PASI90:0,17%,50%),while they were lowest in the severe group.Fifty-six percent of patients reported at least one adverse event during the 12-week period,with the most common being diarrhea(30%),nausea(12%),and muscle pain(6%).Few patients ex-perienced depression,headache,stomachache,or toothache.No serious adverse events occurred.Conclusions Apremilast demonstrates good efficacy for mild to moderate plaque psoriasis.Diar-rhea is the most commonly reported adverse event and is generally well tolerated.关键词
斑块状银屑病/阿普米司特Key words
plaque psoriasis/apremilast引用本文复制引用
ZHU Enyi,ZHI Cuisong,GAN Yichuan,YE Hui,LUO Quan,ZHANG Sanquan,YE Qianru,LI Wei..阿普米司特治疗斑块状银屑病的疗效及安全性[J].皮肤性病诊疗学杂志,2025,32(12):846-851,6.基金项目
广州市科技计划市校(院)企联合资助项目(2024A03J0478) （院）
白求恩公益基金免疫炎症性疾病科研支持项目(J202301E036) （J202301E036）
广州市卫生健康科技一般引导项目(20241A011070) （20241A011070）
